Fig. 2: ESR1 mutations do not affect TP53 expression or TP53 pathway activity in TP53 WT ER + metastatic tumors.
From: Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer
a Box plot showing TP53 mRNA expression between ESR1 WT (n = 19 for MET500; n = 43 for POG570) and mutant (n = 10 for MET500; n = 14 for POG570) in TP53 WT tumors (upper panel) and TP53 mRNA expression between TP53 WT (n = 19 for MET500; n = 43 for POG570) and mutant tumor (n = 15 for MET500; n = 25 for POG570) in ESR1 WT tumors (lower panel) in MET500 and POG570 cohorts. Log2(CPM + 1) values for TP53 gene were extracted from RNA-seq. Box plots span the upper quartile (upper limit), median (center), and lower quartile (lower limit). Whiskers extend a maximum of 1.5× IQR. Mann Whitney U test (two-sided) was applied to each comparison. b Representative images of p53 immunohistochemistry staining of 26 ER+ metastatic tumors from UC cohort. Images were classified by the genotype of ESR1 and TP53. c Dot plots representing p53 IHC quantifications of B in four different groups. Median of each group was indicated. Mann–Whitney U test (two-sided) was used (*p < 0.05; **p < 0.01). d Box plots representing the enrichment levels of four different p53-associated gene signatures between TP53 WT; ESR1 WT (n = 62) and TP53 WT; ESR1 mutant (n = 24) ER+ tumors from merged MET500 and POG570 cohort. Box plots span the upper quartile (upper limit), median (center), and lower quartile (lower limit). Whiskers extend a maximum of 1.5× IQR. Mann–Whitney U test (two-sided) was used.
